Twist Bioscience Co. (NASDAQ:TWST) Given Average Rating of "Moderate Buy" by Brokerages

Shares of Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the ten research firms that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and eight have issued a buy recommendation on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $52.80.

Several equities research analysts recently issued reports on TWST shares. JPMorgan Chase & Co. upped their price target on Twist Bioscience from $35.00 to $40.00 and gave the company an "underweight" rating in a research report on Tuesday, February 4th. Scotiabank reissued an "outperform" rating on shares of Twist Bioscience in a report on Tuesday, February 4th. Guggenheim set a $50.00 price target on shares of Twist Bioscience in a report on Friday, March 28th. Robert W. Baird increased their price objective on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an "outperform" rating in a research note on Tuesday, February 4th. Finally, Barclays decreased their target price on Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating for the company in a research note on Thursday, April 10th.

Twist Bioscience Trading Down 4.3 %

NASDAQ TWST opened at $36.80 on Friday. The company has a market capitalization of $2.20 billion, a price-to-earnings ratio of -10.89 and a beta of 2.34. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62. Twist Bioscience has a 12 month low of $27.41 and a 12 month high of $60.90. The company's fifty day moving average price is $40.75 and its two-hundred day moving average price is $44.47.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.09. The business had revenue of $88.70 million for the quarter, compared to analysts' expectations of $86.96 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The company's quarterly revenue was up 24.1% compared to the same quarter last year. During the same quarter last year, the company posted ($0.75) earnings per share. As a group, research analysts predict that Twist Bioscience will post -2.12 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Twist Bioscience news, CEO Emily M. Leproust sold 1,726 shares of the company's stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $41.68, for a total value of $71,939.68. Following the completion of the sale, the chief executive officer now directly owns 660,966 shares in the company, valued at $27,549,062.88. This represents a 0.26 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Patrick John Finn sold 2,422 shares of Twist Bioscience stock in a transaction on Thursday, January 23rd. The shares were sold at an average price of $50.17, for a total value of $121,511.74. Following the transaction, the chief operating officer now owns 272,044 shares in the company, valued at approximately $13,648,447.48. This trade represents a 0.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 22,796 shares of company stock worth $1,077,383. 3.01% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Barclays PLC lifted its holdings in Twist Bioscience by 214.8% in the 3rd quarter. Barclays PLC now owns 153,039 shares of the company's stock valued at $6,913,000 after acquiring an additional 104,420 shares during the last quarter. Avanza Fonder AB bought a new stake in shares of Twist Bioscience in the 4th quarter worth approximately $1,059,000. Principal Financial Group Inc. raised its holdings in shares of Twist Bioscience by 67.5% in the 3rd quarter. Principal Financial Group Inc. now owns 205,864 shares of the company's stock worth $9,301,000 after purchasing an additional 82,953 shares in the last quarter. Oddo BHF Asset Management Sas acquired a new stake in Twist Bioscience during the third quarter valued at approximately $3,302,000. Finally, Vanguard Group Inc. boosted its holdings in Twist Bioscience by 3.4% during the fourth quarter. Vanguard Group Inc. now owns 5,807,183 shares of the company's stock worth $269,860,000 after buying an additional 189,791 shares in the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.